Nagpur: Clinical trials of a new BCG vaccine for tuberculosis (TB) will begin soon in India, according to Dr Shekhar Mande, former director-general of the Council for Scientific and Industrial Research (CSIR). He was speaking at the ongoing Indian Science Congress here.

Earlier in the day, Dr. Mande gave a presentation on 'Biophysical Methods in Tuberculosis Research' and spoke about how technology has helped doctors and researchers understand TB better, paving ways to combat the infectious disease.

The CSIR is working towards rapid diagnosis, vaccination, and treatment to eliminate the bacterial disease from India by 2025, as envisioned by the government, he said, speaking to reporters later.

Click for more articles on Clinical Trials

"We are mainly focusing on new medicines and drugs for tuberculosis." We are doing background work and setting targets on research for prevention of tuberculosis," he said

The National Institute of Tuberculosis Research, Chennai, will start clinical trials of the new BCG vaccine for TB, he said. The Bacillus Calmette-Guerin (BCG) vaccine is primarily used against tuberculosis.

According to the India TB Report 2022, the number of 'incident TB patients' (new and relapse cases) notified during 2021 stood at 19.3 lakh. On the government's aim to make India TB-free by 2025.

Click for more articles on BCG Vaccine

Dr. Mande said, "There is a very serious effort going across various agencies in the country." "The departments of health research, biotechnologies, and the CSIR are all working toward TB-free 2025."

The goal is a huge challenge as the TB load in India is extremely high, he said. "It is anticipated that about 30 percent of the population is already infected with Mycobacterium tuberculosis (the bacterium that causes TB).

But the good news is that about 90 per cent of that 30 per cent will never ever develop TB in their lifetime. And only 10 per cent of those 30 per cent would develop TB at some point in time."

Click for more on Tuberculosis

The objective is to suppress even those 10 percent. "So, by 2025, we will actually be able to control that particular population and make India TB-free," he said. There are multiple ways to achieve the goal, he said.

"For example, one of the most promising ways of controlling tuberculosis is something called DOTS therapy (directly observed treatment, short-course), in which the patient takes medicine in the presence of a doctor and the therapy is continued for 6 to 8 months and completed as best as possible," Dr. Mande explained.

Forms: Clinical Trial

Schedules: Clinical Trials

Notifications: New Drugs, FDC, Clinical Trial  

Other details about New Drugs, FDCs, Clinical trial    

FAQs by CDSCO on Pharma, Cosmetics, MDR, Clinical Trial

Drug licences of these two firms suspended: FDA Manipur

Fake pharma firm busted, two arrested

USFDA approves Fesoterodine Fumarate Extended-Release tablets

Medical Device alert: CDSCO issues medical device alert on MitraClip Clip Delivery System

Drug recall: Vancomycin Hydrochloride Injection recalled due to this reason

NPPA is in the process of fixing ceiling prices of 63 formulations

List of approved New Drugs Updated

No need to recall, re-label the drug for price revision if…….:NPPA

Registration for sale of Medical Devices: Procedure and conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2023/01/07/new-bcg-vaccine-for-tb-clinical-trials-to-start-soon/